Major publications

• Abdelbaki A, Akman HB, Poteau M, Grant R, Gavet O, Guarguaglini G, Lindon C. (2020). AURKA destruction is decoupled from its activity at mitotic exit but essential to suppress interphase activity.  J. of Cell Science. May 11.
• Delacour Q. and Gavet O. (2017). Re-investigating Polo-like kinase 1 inhibitors as antimitotic agents, Molecular and Cellular Oncology, Author's view, Aug 1;4(6):e1356430

Cell division and genomic stability

This group belongs to:
UMR 9019 Genome Integrity and Cancers - Genome integrity, immune response and cancer

 Lab members

Doctors/Pharmacists
Dr. Ahamadreza ARBAB (PH, Gustave Roussy)
Dr. Sophie BROUTIN (PH, Gustave Roussy)
Dr. Cristina CASTILLA-LORENTE (PH, Gustave Roussy)
Dr. David COMBAREL (AHU, Gustave Roussy)
Dr. David GHEZ (PH, Gustave Roussy)
Pr. Angelo PACI (PU-PH, Paris Saclay)
Dr. Sofia RIVERA (PH, Gustave Roussy)

Major publications

1. Allouch A, Paoletti A, Wu Q, Subra F, Di Pimio C, Cereseto A, Martins I, Voisin L, Dakhli H, Law F, Nardacci R, Saidi H, David A, Solary E, Deutsch E Modjtahedi N, Ojcius DM, Pancino G, Saez-Cirion A, Piacentini M, Gougeon ML, Kroemer G and Perfettini JL. Microtubule-associated SUGT1 protein dictates retroviral trafficking and susceptibility to HIV-1 infection. Cell Death Diff. (2020). doi:10.1038/s41418-020-0573-5.

Cell death, Immunity and Therapeutic Innovation

This group belongs to the UMR 1030 - Molecular radiotherapy and therapeutic innovations

Research topics

With the ambition of optimizing the efficacy of anticancer treatments (in particular radiotherapy), we are developing a research program that aims at identifying and characterizing the mechanisms of anticancer response at genetic, metabolic as well as immunological levels.

Major publications

1. Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Handgretinger R, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy M, Cohn S, Pathiraja K, Diede S, Ebbinghaus S, Pinto N. Phase 1/2 KEYNOTE-051 study of pembrolizumab in pediatric patients with advanced melanoma or a PD-L1+ advanced, relapsed or refractory solid tumor or lymphoma. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. PMID:31812554

Pediatric Precision Medicine and Experimental Therapeutics

This group belongs to the UMR 1015 "Tumour Immunology and anti-cancer immunotherapy".

The aim of our group is to develop new innovative therapies for children with advanced cancers through our clinical precision cancer medicine trials, with one group focusing on osteosarcoma classification and development of new innovative adapted therapies in children, adolescent and young adults.

Lab members

• Nazanine Modjtahedi, DR2, CNRS, team leader
• Lluis M Mir, DRCE, CNRS
• Catherine Brenner, DR2, CNRS
• Franck M André, CRCN, CNRS
• Giorgia Urbinati, CRCN, CNRS
• Jean-Remi Bertrand, IR, INSERM
• Alain Deroussent, IR, CNRS
• Céline Gracia, IE, CNRS
• Dawei Liu, Post-doc, INCA/CNRS
• Camille Reinhardt, Post-doc, INCA/CNRS
• Thai -Hoa Chung, Doc, Université Paris-Saclay
• Amina Ghorbel, Doc, Université Paris-Saclay
• Kenza Nedara, Doc, Université Paris-Saclay

Major publications

• Reinhardt C, Arena G, Nedara K, Edwards R, Brenner C, Tokatlidis K, Modjtahedi N. AIF meets the CHCHD4/Mia40-dependnet mitochondrial import pathway. Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165746. doi: 10.1016/j.bbadis.2020.165746.
• Pervaiz S, Bellot G, Lemoine A, and Brenner C. Redox Signaling in the pathogenesis of human disease and the regulatory role of autophagy. Int Rev Cell Mol Biol. 2020, in press.

Metabolic plasticity in health and disease

This group belongs to the UMR 9018 - Metabolic and systemic aspects of oncogenesis for novel therapeutic approaches (Metsy)